Printer Friendly

THE IMMUNE RESPONSE CORPORATION FILES TWO INVESTIGATIONAL NEW DRUG APPLICATIONS FOR AUTOIMMUNE DISEASE TREATMENTS

 SAN DIEGO, Nov. 4 /PRNewswire/ -- The Immune Response Corporation (NASDAQ-NMS: IMNR) today announced that it has filed two Investigational New Drug (IND) applications with the Food and Drug Administration to test therapeutic vaccines for multiple sclerosis and rheumatoid arthritis in separate Phase I human clinical trials. Subject to FDA concurrence, each trial is expected to be initiated in early 1994.
 The trial to test a multiple sclerosis therapeutic vaccine (AI208) will represent the initial safety testing for this product in humans. The clinical trial, which is expected to involve 10 patients, has been designed in collaboration with the San Diego Regional Cancer Center, San Diego.
 The IND filed for the rheumatoid arthritis therapeutic vaccine (AI204) is the third IND the company has filed for this indication. Sixteen patients are expected to be involved in the Phase I clinical trial for AI204. The company's two other potential products, AI201 and AI205, undergoing clinical trials in rheumatoid arthritis patients, are progressing on schedule.
 Each of these products under development specifically targets receptors on the autoreactive T cells. The company believes that these autoreactive T cells initiate the attack against normal tissue resulting in the development of autoimmune disease.
 The Immune Response Corporation is a biopharmaceutical company engaged in the development of proprietary products for the treatment of HIV infection and autoimmune diseases and, through TargeTech Inc., gene therapy.
 -0- 11/4/93
 /CONTACT: Bronwyn LeMelle or Cynthia Rollins, investor relations, of The Immune Response Corporation, 619-431-7080/
 (IMNR)


CO: The Immune Response Corporation ST: California IN: MTC SU:

LS-JL -- SD001 -- 0490 11/04/93 08:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 4, 1993
Words:264
Previous Article:KRISSEL ELECTED PSSU PRESIDENT, BACON AS SECRETARY-TREASURER
Next Article:BOEING DEVELOPING MODULAR, MULTI-ROLE TACTICAL AIRPLANE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters